Compare Quest Diagnostics Inc (DGX) vs NIO Inc. (NIO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs NIO Inc. — how do they compare? Quest Diagnostics Inc trades at $237.5 (market cap $26.21B), while NIO Inc. trades at $4.57 (market cap $11.59B). The key difference: Quest Diagnostics Inc is far larger — about 2.3× NIO Inc.'s market cap, and Quest Diagnostics Inc pays a 1.45% dividend while NIO Inc. pays none. Which is the better fit depends on your goals.
| DGX | NIO | |
|---|---|---|
Market Cap | $26.21B | $11.59B |
Sector | Health | Consumer Cyclical |
52-Week High | $238.50 | $7.89 |
52-Week Low | $173.49 | $4.44 |
Enterprise Value | $31.97B | $10.82B |
Dividend Yield | 1.45% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $237.63, down slightly by 0.3% today, but maintains strong momentum with three consecutive quarterly earnings beats and a raised 2026 outlook. The stock shows bullish technical signals with moving averages supporting upward trends, while fundamentals reveal solid revenue growth to $11.04 billion in 2025 and improving profit margins. Recent news highlights surging testing demand and AI implementation driving operational efficiency.
DGX presents a favorable investment case with analyst consensus price target of $249.50 offering 5% upside potential. Strong testing demand, strategic partnerships, and earnings momentum support growth, though elevated debt levels and margin pressures from lower-margin deals pose moderate risks. The stock's current valuation at 25.21 P/E appears reasonable given growth prospects.
NIO's stock trades at $4.575, down 5.08% amid bearish technical signals and negative cash flows. Revenue grew to $87.49 billion in 2025, but net losses persist at -$15.57 billion. Recent news highlights delivery growth and competitive pressures in China's EV market, with shares near support levels after a steep decline from 2026 highs.
The outlook remains challenged by profitability concerns and high debt, though analyst consensus leans bullish with 54% buy ratings. Key risks include intense competition and reliance on financing, while potential upside hinges on margin improvement and sustained delivery growth in a volatile sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About NIO Inc.
NIO Inc. manufactures and sells automobiles. The Company offers electric vehicles and parts, as well as provides battery charging services. NIO serves customers worldwide.
Read more on NIO →
